Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/23189
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMahalatchimy, A-
dc.contributor.authorLau, PL-
dc.contributor.authorLi, P-
dc.contributor.authorFlear, ML-
dc.date.accessioned2021-09-09T15:33:25Z-
dc.date.available2021-09-09T15:33:25Z-
dc.date.issued2021-08-16-
dc.identifier.citationMahalatchimy, A., Lau, P.L., Li, P. and Flear, M.L. (2021) 'Framing and legitimating EU legal regulation of human gene-editing technologies: key facets and functions of an imaginary', Journal of Law and the Biosciences, 8 (2), lsaa080, pp. 1-30, doi: 10.1093/jlb/lsaa080.en_US
dc.identifier.urihttps://bura.brunel.ac.uk/handle/2438/23189-
dc.description.abstractCopyright © The Author(s) 2021. Gene-editing technologies, ie those able to make changes in the DNA of an organism, are the object of global competition and a regulatory race between countries and regions. There is an attempt to craft legal frameworks protective enough for users, but flexible enough for developers of gene-editing technologies. This article examines the imaginary built into the framing of EU-level legal regulation of human gene-editing technologies and identifies its three key related facets: the tension around naturalness; safeguarding morality and ethics; and the pursuit of medical objectives for the protection of human health. Concerns around the use of gene-editing technologies in relation to eugenics and human enhancement have produced a multifaceted imaginary. We argue that this imaginary not only places a limit on EU-level regulation, despite a strong EU competence in respect of the internal market, but also seeks to ensure its legitimation.en_US
dc.format.extent1 - 30-
dc.format.mediumElectronic-
dc.languageEnglish-
dc.language.isoenen_US
dc.publisherOxford University Press on behalf of Harvard, Duke and Stanford Law Schoolsen_US
dc.rightsCopyright © The Author(s) 2021. Published by Oxford University Press on behalf of Duke University School of Law, Harvard Law School, Oxford University Press, and Stanford Law School. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. This is an Open Access article distributed under the terms of the Creative Commons Attribution NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.subjectEuropean Unionen_US
dc.subjectframingen_US
dc.subjectgene editingen_US
dc.subjectimaginariesen_US
dc.subjectlawen_US
dc.subjectScience and technology studiesen_US
dc.titleFraming and legitimating EU legal regulation of human gene-editing technologies: key facets and functions of an imaginaryen_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.1093/jlb/lsaa080-
dc.relation.isPartOfJournal of Law and the Biosciences-
pubs.issue2-
pubs.publication-statusPublished-
pubs.volume8-
dc.identifier.eissn2053-9711-
Appears in Collections:Brunel Law School Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdf453.9 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons